Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm PONY Biomedicine to co-develop a comprehensive one-stop service platform for small and large molecule drugs in the pre-clinical stage. This collaboration aims to offer competitive technical services and solutions to biopharmaceutical clients on a global scale. The financial terms of the agreement have not been disclosed.
Novopathway is renowned for its expertise in the field of disease animal modeling, while PONY Biomedicine boasts an extensive technical service platform that encompasses drug design, synthesis, efficacy evaluation, structural optimization, formulation research, pharmacodynamic and pharmacokinetic assessments, toxicological evaluations, and support for new drug regulatory filings.- Fineline.com
